Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2- Ductal and Lobular Breast Cancer”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Early research (Phase 1)Looking for participantsNCT06562192
What this trial is testing

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast Cancer+2 more
Novartis Pharmaceuticals 162
Early research (Phase 1)Looking for participantsNCT07630961
What this trial is testing

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Who this might be right for
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)HR+/HER2- Ductal Breast Cancer (BC)+4 more
Novartis Pharmaceuticals 66
Early research (Phase 1)Looking for participantsNCT07261631
What this trial is testing

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-Small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast Cancer+3 more
Novartis Pharmaceuticals 180
Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725